U.S. Markets open in 2 hrs 48 mins

HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance

Priya Nigam

La Jolla Pharmaceutical Company (NASDAQ: LJPC) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million for the drug. 

The guidance represents continued linear growth, despite the company’s plans efforts to reach an inflection point in Giapreza’s sales by moving to centralized contracting and offering volume discounts, according to H.C. Wainwright.

The Analyst

Analyst Edward White maintained a Buy rating on La Jolla and reduced the price target from $48 to $25.

The Thesis

La Jolla expects a decision in June on its Marketing Authorization Application to the European Medicines Agency for Giapreza, White said in a Wednesday note. 

If Giapreza receives EMA approval, it could be launched in Europe in the back half of 2019, according to La Jolla. 

The impact of the below-expectation Giapreza sales guidance for 2019 is offset partially by cost-cutting expectations in R&D and SG&A, the analyst said. 

H.C. Wainwright reduced its revenue estimates for the company from $17.5 million to $10 million in 2018 and from $89.7 million to $24.8 million in 2019. EPS estimates for 2018 were lowered from a $7.96 loss to an $8.16 loss and from a $6.03 loss to a $7.31 loss in 2019.

Price Action

La Jolla Pharmaceutical shares were rallying nearly 16 percent to $6.32 at the time of publication Wednesday. 

Related Links: 

The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug 

Latest Ratings for LJPC

Date Firm Action From To
Aug 2018 JP Morgan Maintains Underweight Underweight
Aug 2018 Jefferies Maintains Underperform Underperform
Feb 2018 Jefferies Downgrades Buy Underperform

View More Analyst Ratings for LJPC
View the Latest Analyst Ratings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.